Q2 2026 Tonix Pharmaceuticals Holding Corp Earnings Call Transcript
Key Points
- TONMYA net sales reached $11 million in Q2 2026, a 197% quarter-over-quarter increase, demonstrating strong commercial momentum.
- Prescriptions for TONMYA totaled 12,592 in Q2, a 100% quarter-over-quarter increase, with refills up 207%, indicating strong patient adherence and durability.
- Market access coverage expanded to 136 million covered lives (43% of the U.S.), with agreements expected to increase coverage to 145 million lives by January 2027.
- The company plans to expand its sales force to 150 reps by September 2026, enhancing its ability to target high-prescribing HCPs and drive further growth.
- TNX-102SL for major depressive disorder (MDD) advanced with the first patient randomized in the potentially pivotal Phase 2 HORIZON study, and TNX-4800 for Lyme disease prevention received positive FDA feedback on its Phase 2 study design.
- The company's cash position decreased to $176.2 million as of June 30, 2026, from $207.6 million at the end of 2025, with funding only expected to last into early Q2 2027.
- Selling, general, and administrative expenses increased significantly to $36 million in Q2 2026, up from $16.2 million in Q2 2025, driven by launch-related costs.
- Research and development expenses rose to $19.4 million in Q2 2026, up from $10.8 million in Q2 2025, reflecting increased pipeline investment.
- Gross-to-net fluctuations are expected in Q3 and Q4, which could impact net sales and profitability.
- The TNX-4800 Phase 2 study for Lyme disease prevention is large and complex, with enrollment of approximately 3,300 participants and a potential extension into 2029 if attack rates are lower than expected.
Good morning, and welcome to Tonix Pharmaceuticals' Second Quarter 2026 Financial Results and Business Update Conference Call. (Operator Instructions) I would like to turn the call over to Deborah Elson, Head of Investor Relations at Tonix Pharmaceuticals. Please go ahead.
Thank you, operator, and good morning, everyone. We appreciate you joining us today to discuss Tonix Pharmaceuticals Second Quarter 2026 Financial Results and Operational Highlights. Before we begin, I would like to remind everyone of the disclaimers on slide 2 that any statements made on today's call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1,995. These statements are based on management. Current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks are described more fully in our filings with the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
